INSIDE THE OPERATING ROOM
ventions that may be available for the condition. In assessing how new procedures should be introduced, I believe we need to distinguish between coverage and validation. Coverage-ie, payment for the procedure-is an economic issue, whereas validation involves an ethical and scientifi c evaluation of the role of the procedure.
Coverage by an insurer should have at least theoretical justifi cation and presumption of benefi t. For instance, the rationale behind a heart transplant for a patient with a failing heart is obvious. Coverage generally requires preliminary evidence of effi cacy, possibly in an animal model, although no animal models may exist for some conditions. Most important, a different standard for providing initial coverage should be applied if no alternative therapy exists for a condition that is severe, debilitating, and potentially life-threatening; if a new procedure treats a condition for which a standard therapy already exists, the standard for coverage must be higher. Finally, coverage in all cases should require ongoing reassessment of the procedure.
In contrast, validation is a scientifi c analysis of results over time, including long-term results, and can be accomplished by well-controlled case series, particularly if the magnitude of the benefi t is both frequent and signifi cant and especially if no alternative therapy exists. Randomized clinical trials are the gold standard for appropriate interventions but are not always applicable.
A 1996 study by Majeed et al 2 provides a good example of validation-oriented surgical research. In this blinded trial, 200 patients scheduled for cholecystectomy were randomized to either laparoscopic or open (small-incision) procedures. The study found no differences between the groups in terms of hospital stay or postprocedure pain or recovery. In an accompanying commentary, 3 Lancet editor Richard Horton praised the design and conduct of the study, noting that it was very much the exception in surgical research, which he argued was preoccupied with case series. Horton offered the following speculation about this preoccupation:
Perhaps many surgeons do not see randomised trials as feasible strategy to resolve questions about surgical management. Cynics might even claim that the personal attributes that go to make a successful surgeon differ from those needed for collaborative multicentre research. 3 
IS THE 'SURGICAL SCIENTIST' AN OXYMORON?
Barnaby Reeves, writing in The Lancet 3 years later, offered a more diplomatic take on the diffi culty of evaluating surgical procedures:
What makes a surgical technique new is not always easy to defi ne because surgical procedures generally evolve in small steps, which makes it diffi cult to decide when a procedure has changed suffi ciently to justify formal evaluation. 4 Reeves went on to argue that doing an evaluation too early may preclude acceptance, since the technique may not have evolved suffi ciently and surgeons may not have mastered it; conversely, doing an evaluation too late may make the evaluation moot, since the technique may have already become established and withholding it may be deemed unethical. Additionally, he noted that the quality of surgical evaluation is complicated by the possibility that some surgeons have better mastery of-and therefore better outcomes with-one procedure while other surgeons have better mastery and outcomes with an alternative procedure. 4 These concerns were well captured by the late Dr. Judah Folkman, whom I once heard say, "When a basic scientist is informed that another investigator cannot reproduce his work, it has a chilling effect; for the surgeon, however, it is a source of pride."
RANDOMIZED TRIALS VS CASE SERIES:
A TIME AND PLACE FOR EACH Even as we recognize these challenges specifi c to surgical evaluation, we are still left with the task of determining when a randomized controlled trial is appropriate and when a case-control series may suffi ce.
There are three broad sets of circumstances in which a randomized trial is essential:
For preventive procedures, ie, when the opera-• tion is done to reduce the potential for a future adverse event. An example would be evaluating carotid endarterectomy to reduce the potential for stroke in asymptomatic patients with 60% or greater stenosis. Only a randomized trial could have shown a difference in favor of endarterectomy over aspirin plus best medical therapy.
To compare a procedure with alternative medi-• cal or surgical interventions. I would argue that laparoscopic surgery should have been introduced with randomized trials, as it begs one to suspend judgment One of our duties when conducting studies is not just to answer unanswered questions but to question unquestioned answers.
-Dr. Joel Cooper
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and accept that small incisions are invariably and de facto better than a large incision.
For trials in oncology, where the outcome • depends on long-term results, such as survival or time to recurrence. Examples would include comparisons of surgery alone versus surgery plus chemotherapy for prevention of cancer recurrence.
Similarly, there are several scenarios in which a case-control series is appropriate and adequate:
When no alternative therapy exists. Falling • into this category, in my view, are lung transplant, which we introduced successfully at the University of Toronto in 1983, and lung volume reduction surgery, which we introduced in 1993.
When the natural history of the condition is • well documented and the impact of the intervention is obvious.
When the magnitude of the procedure's effect is • measurable, signifi cant, and expected.
RANDOMIZED TRIALS IN SURGERY
Advantages of randomized trials
Randomized clinical trials confer a number of advantages. They eliminate bias. They ensure a balance between treatment groups in terms of known or unknown prognostic factors. And, importantly, they have a major impact on payors.
A tale of two Medicare payment decisions
The impact of clinical trials on payors is exemplifi ed by the contrasting stories of two procedures: transmyocardial laser revascularization and lung volume reduction surgery.
Transmyocardial laser revascularization (TMR) involves the creation of channels in the myocardium with a laser to relieve angina. Although TMR is a dubious intervention with no physiologic rationale (similar to internal mammary artery ligation for angina 5 ) and no proven improvement in life expectancy (only a reduction in pain), it was approved for reimbursement by Medicare because it was investigated in a randomized trial. 6 However, the "randomized trial" was not truly a randomized investigation because the control patients received only medical therapy and did not go to the operating room to receive a sham operation. 6 Despite this fl aw, the perceived authority of the trial was suffi cient to infl uence Medicare.
In contrast, Medicare refused to pay for lung volume reduction surgery until it was subjected to a randomized trial, despite the fact that the procedure had produced tremendous benefi t in hundreds of patients at multiple centers who otherwise could not have achieved such benefi t. Only after $50 million was spent on a randomized controlled trial, the National Emphysema Treatment Trial (NETT), [7] [8] [9] did Medicare agree to pay for lung volume reduction surgery. The trial showed that over 5 years, the procedure was associated with signifi cant improvements in life expectancy, exercise tolerance, and quality of life, but the study took 8 years to conduct and by then it was a bit too late, as detailed in the following section.
NETT: A case study in how a trial can be counterproductive Lung volume reduction surgery is an operation based on the recognition that the crippling effects of emphysema are hyperinfl ation of the chest, fl attening of the diaphragm, and inability to move air in and out of the chest. The notion that the chest can be reconfi gured in the patient with emphysema by removing the distending overinfl ated emphysema led us to develop the volume reduction operation. The NETT was initiated by Medicare, and the protocol denied compassionate crossover of patients. 7 In an attempt to establish clinical equipoise, surgeons who participated were not allowed to perform any volume reduction operations on non-Medicare patients or on Medicare patients not enrolled in the trial. After 2 years of slow patient enrollment, the clinical trial committee, in an effort to increase enrollment, eliminated the original entrance criteria specifying certain degrees of hyperinfl ation and diffusing capacity. An excess of mortality was discovered 2 years later in a subgroup randomized to volume reduction surgery;
8 not surprisingly, further analysis showed that the excess mortality was largely confi ned to patients who would have been excluded based on the original entrance criteria. This is a matter of public record but was never acknowledged in published reports of the trial. Final 5-year NETT results showed that in patients with upper lobe emphysema, lung volume reduction surgery improved survival, increased exercise capacity, and improved quality of life. 9 By the trial's completion, however, the procedure's reputation had been tarnished irreparably by bad publicity from the deaths attributable to the misguided changes to the original eligibility criteria. 
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Disadvantages of randomized trials
The NETT exemplifi es many of the drawbacks of randomized trials in surgery, particularly the need to wait long periods while they are being conducted. During the 8 years in which the NETT was ongoing, the number of lung volume reduction operations declined, with the typical center performing fewer than 6 cases per year, on average. That limitation is certainly not conducive to the development of a new procedure for a disabling condition in patients with no ready alternative.
Other disadvantages of randomized trials in surgery are their considerable expense and the fact that they often are not generalizable and often are not appropriate. Moreover, when they are fl awed, randomized trials propagate, sometimes for decades, misleading information that is nonetheless considered "authoritative." For instance, lung cancer kills more men and women in the United States than the next three cancers combined, yet, on the basis of a fl awed randomized trial, 10 the American Cancer Society advises smokers to wait for symptoms before undergoing chest radiography, instead of recommending annual screening chest radiography. This is a major reason why two-thirds of lung cancer cases are discovered too late to save the patient.
'Better to know nothing than to know what ain't so' Indeed, this potential for randomized clinical trials, when fl awed, to propagate misleading information makes the perceived authoritativeness of randomized trials both an advantage and a disadvantage. As Berger and colleagues noted a few years ago, overuse of randomized trials for evaluating emerging operations could have led to the demise of heart transplantation, mechanical circulatory assist devices, cardiac valve procedures, coronary bypass grafting, and repair of congenital lesions.
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For this reason, one of our responsibilities when reading the literature and conducting studies is not just to answer unanswered questions but to question unquestioned answers. As 19th-century humorist Josh Billings put it, "It's better to know nothing than to know what ain't so."
A PERSONAL PERSPECTIVE
In my view, health care providers should restrict the application of new procedures to a limited number of centers of excellence that have appropriate resources and experience. Those centers should be required to document and report specifi ed information regarding morbidity, mortality, and objective measures of outcome; if they do not comply, they should lose the privilege of doing such research. The data should be reviewed by an independent, nongovernmental scientifi c panel. In this way, the procedure can be offered to appropriate patients, insurers and patients can be protected against abuse, and the necessary data can be collected for objective analysis. Change in the surgical world involves three aspects, which I refer to as the three Ds: discovery, development, and dissemination. Change requires proof that the new method is superior to the old. When we, as innovators, develop something "new," I believe that our immediate subsequent task is to do everything we can to prove that this "new" fi nding is of no value whatsoever before we determine that it is worth advancing.
Idea to implementation
Getting to Malcolm Gladwell's tipping point-the act or event after which nothing is ever the samerequires a team of people, usually from different disciplines, coming together to concentrate on a problem, or an individual whose experiences in different fi elds provides the ability to "see" the next level. In my opinion, one person working in one discipline rarely leads to breakthrough progress in medicine.
These observations about surgical innovation stem largely from my experience in the development of laparoscopic nephrectomy, in which I was privileged to play a role while at Washington University in St. Louis, which I will outline here.
THE HISTORY BEHIND LAPAROSCOPIC NEPHRECTOMY
After doing preliminary work in dogs, the German surgeon Gustav Simon performed the fi rst human nephrectomy in 1869, in a woman with a ureteral vaginal fi stula. The operation was a success: it took him 50 minutes to complete the procedure, and 6 months later the patient went home.
From that point in 1869 until 1990, progress in nephrectomy was minimal, with open surgery remaining the gold standard. While the surgeon's tools remained largely unchanged, the advances that did occur were in anesthesia, analgesia, and antibiotics, which allowed patients to better survive the onslaught of the operation.
In an unrelated arena, laparoscopy was developed in 1901 by another German surgeon, Georg Kelling, who pumped air into the peritoneal cavity of a dog in a successful effort to stop bleeding from the stomach. Within the pneumoperitoneum, Kelling was able to examine the canine organs with a cystoscope at pressures as high as 140 mm Hg. This discovery was not applied clinically, however, until 9 years later when the Swedish gastroenterologist H.C. Jacobeus used Kelling's pneumoperitoneum concept and a cystoscope to visualize the peritoneal cavity to search for cancer. The technique advanced little in the subsequent decades-apart from Semm's seminal laparoscopic removal of the appendix in the 1960s-until 1985, when the fi rst laparoscopic gallbladder removal ignited the era of laparoscopic cholecystectomy.
Three technological developments spurred this recent surge in laparoscopy: (1) the ability to affi x a camera to the endoscope, (2) the ability to display the camera's images on a video screen, and (3) the development of self-feeding clip appliers to allow occlusion of vascular or ductal structures.
THE EVOLUTION OF LAPAROSCOPIC NEPHRECTOMY Discovery
I became interested in the possibility of laparoscopic nephrectomy during the laparoscopic cholecystectomy craze in the late 1980s. At that time, I was working with Dr. Nat Soper, performing laparoscopic cholecystectomies in pigs to show that the procedure could be done safely with electrocautery rather than a laser. As it turns out, the anatomy of the porcine kidney is such that the colonic refl ection lies medial rather than lateral to the organ. As such, the kidney is quite visible as soon as one enters the abdomen. Indeed, the kidney seemed to be saying to us, "Hey, what about me? I could come out through that hole too." That is basically how the idea arose.
So, along with Dr. Lou Kavoussi and many others in our research team, we attempted laparoscopic nephrectomy in the pig and succeeded: the kidney could be removed through a small hole by entrapping it in a sack, breaking it up in the sack, and pulling it out. 12 The team involved in this discovery were specialists in urology and general surgery as well as biomedical engineers from industry, specifi cally a team from Cook Urological led by Mr. Fred Roemer.
After performing this technique numerous times in the laboratory, we reduced the operation's duration to 90 minutes, at which point we believed the procedure had advanced suffi ciently to be considered for clinical use.
Development
The patient we selected for the initial clinical case was an 85-year-old woman with a 3-cm mass in her kidney. She was deemed to be "too sick to operate on," so she was presented to me as a candidate for the new laparoscopic procedure.
Amazing as it may seem in our current medical climate, at that time (1990) we were faced with the question of whether or not to seek institutional review board (IRB) approval. The argument could be made that since radical nephrectomy had been practiced for 120 years and laparoscopy had been around for nearly 100 years, the combination of these two well-accepted procedures might require nothing more than physicianpatient informed consent. However, the concept of "informed consent" in this context was problematic: what could we tell the patient about a procedure that had never been done before except that if it was not working out we would convert to the standard open procedure?
A senior colleague-actually my boss at that time, Dr. Bill Catalona-sagely advised me to get IRB approval, noting, "If the operation works out well, you'll be fi ne, but if it doesn't work out well, they'll kill you if you don't have approval." So we fortunately ended up seeking (and receiving) IRB approval, as well as providing, as best we could, informed consent to the patient and her best friend.
Our next consideration was designating a team member to determine if and when conversion to open surgery would be necessary. We needed a "referee" to aid in objectively determining a point at which we should convert. For our team, that person was Dr. Teri Monk, our anesthesiologist, who had no previous experience with our laboratory work but understood When innovators develop something "new," our immediate subsequent task is to do everything we can to prove that it is of no value whatsoever before we determine that it is worth advancing. 
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what we were attempting. So we proceeded with the fi rst clinical laparoscopic nephrectomy on June 25, 1990 . The kidney was embolized the morning of the procedure. Five laparoscopic ports were placed. The clip appliers proved too small for renal vein occlusion, so the main renal vein had to be traced to its branches; in total we clipped fi ve separate sets of renal vascular branches. The kidney was ensnared and morcellated, which took 7 minutes. Total operative time was 6.8 hours. The complications that arose were not anticipated:
Intraoperative oliguria due to the prolonged • pneumoperitoneum Fluid overload (postoperative congestive heart • failure) due to providing fl uids to the patient as though this were an open procedure Dilutional anemia, again due to providing exces-• sive fl uids for a closed procedure.
Postoperative pain medications consisted of one dose of morphine sulfate. The patient was discharged on postoperative day 6 and resumed normal activities by postoperative day 10.
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Dissemination
Before a new procedure is disseminated, evidence of the four Es-effi ciency, effectiveness, equanimity, and economy-must be obtained. In retrospective reviews, laparoscopic removal was associated with a slightly longer operating time but much less blood loss, a shorter hospital stay, and fewer complications. The immediate cancer cure rate was the same for open and laparoscopic nephrectomy, and over time the laparoscopic procedure has been shown to be just as good as open surgery at 5 and now 10 years. Also, with time, laparoscopic nephrectomy was shown to reduce institutional costs.
The next question was the proper way to disseminate this knowledge. At Washington University we took the traditional route of providing courses, offering 17 courses on laparoscopic surgery to nearly 1,000 urologists from 1985 to 2002. But as Winfi eld and associates later showed, only 54% of urologists who completed a 2.5-day hands-on, laboratory-based laparoscopic course actually ended up introducing laparoscopy into their practice. 14 The challenge of dissemination is still with us, and we need to fi nd better methods of transferring new skills to our surgical colleagues. In this regard, longer experiences, such as weeklong mini-fellowships and the development of procedure-specifi c surgical simulators, hold great promise.
UNANSWERED CHALLENGES, UNMET NEEDS
With the advent of any technology comes a cornucopia of unanswered questions and challenges. In the areas of discovery and development, a key question is whether every procedure performed using a new Food and Drug Administration (FDA)-approved technology requires a separate approval by the IRB and ethics committee. For instance, if robotic prostatectomy is approved and performed, are separate approvals needed for robotic nephrectomy, robotic pyeloplasty, and robotic vasectomy? Where would or should the approvals end?
With respect to dissemination, many questions remain: How is a new technology taught effectively? How is surgical competency tested? How is clinical performance or profi ciency evaluated? One problem specifi c to dissemination is a lack of funding. While ample funding is available for discovery and development, as they bring prestige and profi t, dollars are scarce for dissemination, or the teaching and testing of competency and profi ciency with new procedures.
Evidence of our failure to educate the postgraduate surgeon abounds in terms of poor outcomes and malpractice suits. The response of government all too often is the knee-jerk reaction to protect (ie, regulate), not educate. To be sure, we can do better, but only if our society commits to the process-not with words, but with funded educational action.
With regard to the last, I believe there is an unmet need for the development of accurate, validated surgical simulators. As a society, we need to fi nd a way to fund the development of simulators for each surgical subspecialty and then use these devices to objectively test an individual surgeon's manipulative skill as well as cognitive ability when he or she seeks certifi cation or recertifi cation-and perhaps, albeit in an abbreviated 5-minute format, before beginning each operative day. We owe this to ourselves, but most of all to our patients, who in all confi dence place their lives in our hands.
As a society, we need to fi nd a way to fund the development of simulators for each surgical subspecialty and use these devices to objectively test surgeons' skills.
-Dr. Ralph Clayman
If we surgeons take a step back and consider for a moment what has changed in the operating room (OR) in the past 50 to 60 years, the clear answer is, "Just about everything." The monitors, pumps, transport devices, and OR tables and lights have all changed dramatically, as have the tools, catheters, sutures, energy sources, scopes, staplers, ports, valves, and joints. If we consider technologies outside the OR that guide what we do inside the OR, the changes are just as striking. Circulatory assist devices for the failing heart and widespread use of dialysis for the failing kidney postdate 1950, as does all of our modern imaging capability-ultrasonography, computed tomography, magnetic resonance imaging, positron emission tomography, functional imaging. As for pharmacotherapy in 1950, there were three antibiotics, no antivirals, one antifungal, and three chemotherapeutic agents. Open drop ether was the anesthetic of choice. Not only have the tools and technologies changed, but virtually every procedure has been changed. Both our profession and the industry that has developed these devices and tools can be rightfully proud.
It is likewise necessary to recognize that our patients have been partners in this innovation. Many of them have given informed consent to participate in research and experimental procedures with the expectation that the benefi ts might accrue only to future patients and not to themselves. That is a hell of a contribution, and we can be proud of our patients' partnership.
THE GOOD, THE BAD, AND THE UGLY OF INNOVATION
The history of progress in surgical care is always about innovation, and such progress almost always begins with an unsolved patient problem, regardless of the solution that is developed, be it a tool, a device, a technology, or a surgical procedure. At the same time, any discussion of the ethics of surgical innovation should recognize that while efforts to solve patient problems over the years have had many good results, they have also had some bad results and even the occasional ugly result.
This conference has already focused on much of the good that has come from surgical innovation, including transplantation, remarkable advances in cardiac and gastrointestinal surgery, a host of devices, and too many other benefi ts to list. Yet missteps have been made along the way, such as bloodletting, gastric freezing as a therapy for ulcer, and carotid denervation for treatment of asthma in children.
Then there are the ugly incidents, and these notably include a number of cases involving children, an issue of special interest to me as a pediatric surgeon. Consider the following examples: Edward Jenner's notorious cowpox experiment • in the late 18th century was conducted in an 8-yearold boy.
• A well-documented literature shows that orphans were used as subjects for tuberculosis and syphilis inoculations.
• The more recent case of Jesse Gelsinger involved a teenager with a nonlethal condition who died in a clinical trial of gene therapy, after which an undisclosed fi nancial interest on the part of one of the treating physicians was revealed.
It should give us pause to note that many of these practices that look foolish in hindsight probably seemed more rational at the time they were undertaken.
CHILDREN: THE ORPHANS OF INNOVATION
Children have been the orphans of innovation, as technology development specifi cally for children has traditionally been a low priority. There are several reasons for this:
FDA standards for approving therapies in • children are high. For instance, the vast majority of chemotherapeutic drugs are not approved for use in children because conducting a trial specifi cally in children is deemed too expensive.
Pediatric markets for therapies are small.
•
The payor mix is poor. • The benefi ts of duality Nevertheless, children have benefi ted enormously from the duality of technology development, in which a technology developed for one population-either adult or pediatric-ends up benefi ting both populations. For instance, no one would have invented the pulse oximeter to care for a child, yet now it is the 
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only device with which infants and children are monitored in the operating room and during transport.
Likewise, in some cases the solutions to pediatric problems have had reciprocal benefi ts in adults. Ligation of the patent ductus arteriosus and the BlalockTaussig shunt for tetralogy of Fallot opened the door to our understanding of surgery on the great vessels and ultimately enabled the development of cardiac surgery. Similarly, the early impetus for Thomas Starzl's groundbreaking work in transplantation was focused on children with biliary atresia even though this work is now much more widely applied in adults. 
ETHICAL PRINCIPLES APPLY EQUALLY TO ADULTS AND CHILDREN
SPECIAL CONSIDERATIONS IN PEDIATRIC SURGERY: A CASE STUDY IN MATERNAL-FETAL MEDICINE
The Belmont Report, mentioned above, was developed by the US government in 1979 to form the basis of regulations for federally funded research involving human subjects. 17 The report identifi ed three basic principles that must underlie such research:
Respect for persons-protecting the autonomy • of all subjects, treating them with courtesy, and allowing for informed consent Benefi cence-maximizing benefi ts from the • research initiative while minimizing risks to the subjects Justice-ensuring reasonable, nonexploitative, • and well-considered procedures that are administered fairly.
In pediatric surgery, everyone agrees that the "best interests of the child" must be protected, but the issue of autonomy (a key element of the fi rst Belmont principle) is more diffi cult to defi ne, of course, when the patient is a child rather than an adult. The question of autonomy is especially tricky in the evolving fi eld of maternal-fetal medicine: what if the patient is a fetus and the mother is an innocent bystander?
Over the past 20 years, tremendous progress has been made in our understanding of diseases of the fetus, particularly diseases that limit fetal viability and diseases that cause serious organ damage but which may be more responsive to postnatal therapy if they are treated prenatally. Michael Harrison, N. Scott Adzick, and a few of their disciples have laid the ethical groundwork for consideration of the fetus as a patient.
Considerations in maternal-fetal medicine I will conclude with a case in maternalfetal medicine for us to consider and perhaps debate in the panel discussion at the end of this session. As you consider this case, keep in mind several important observations relating to maternal-fetal medicine:
• The mother's health interests cannot be underestimated.
• Most "fi xable" fetal lesions (ie, those that interfere with development and cannot be fi xed postnatally, but for which intervention in utero may result in normal development) are very rare. They include obstructive uropathy, lung lesions causing hydrops, congenital diaphragmatic hernia, sacrococcygeal teratoma, hydrocephalus, twin-twin transfusion syndrome, congenital high airway obstruction, hydrothorax, myelomeningocele, and congenital heart disease.
The fi eld is evolving, and the effi cacy of therapy • is supported by variable level I, II, and III evidence.
The law has not kept (and perhaps cannot keep) • pace with developments in this fi eld.
Case study
A 24-year-old healthy woman has a fetus of 28 weeks' gestational age with progressive lower urinary tract Many ethically ugly practices from the past look foolish in hindsight but probably seemed more rational at the time they were undertaken.
-Dr. Thomas Krummel obstruction with megacystis, bilateral hydronephrosis, and oligohydramnios. In other words, there is diminished volume in the uterine cavity that causes compression of the fetal chest and subsequent respiratory compromise that will be fatal if not addressed. The karyotype is a normal 46,XY male. Serial urine sampling reveals electrolyte and protein profi les with a good prognosis.
Prenatal counseling with fetal therapy specialists suggests that this is the "perfect case" for a vesicoamniotic shunt. This is the least invasive, most successful fetal surgical intervention. It is done under local anesthesia and involves transabdominal transuterine percutaneous placement of a double-lumen pigtail catheter in the fetal bladder. There has never been a reported maternal death, and morbidities have been minimal. Renal and pulmonary function both are improved by approximately 80% in fetuses treated with this intervention, and survival is improved.
The father is eager to proceed. The mother is ambivalent. Should the mother be pressured to proceed, for the good of the child?
Questions to ponder
The following questions are intended to be provocative, with no clear-cut answers:
Should (or does) the fetus have independent • moral status? Is it full, graded, or none? Does it matter?
What are the benefi cence-based obligations to the • fetus? At 28 weeks' gestation, the fetus is viable outside the uterus. The fetus is otherwise well, without a lethal karyotype, and has currently good renal function.
What are the benefi cence-based and autonomy-• based obligations to the mother? What are the mother's obligations to the fetus?
What if the mother ultimately decides to pro-• ceed and the insurance company denies coverage? What are the social responsibilities to care, cost, and research?
These questions lend themselves to discussion. As much as we surgeons like to be certain about what we do, we would do well to heed the quote from Voltaire that the great surgeon Norman Shumway hung on his offi ce door: "Doubt is not a very agreeable state, but certainty is a ridiculous one." Obesity is a staggering problem: 100 million Americans are overweight, 85 million more are obese, and another 15 million are morbidly obese (ie, у 100 lbs above ideal body weight). The incidence of obesity is rising rapidly and threatens to shorten the life spans of today's young generations relative to their parents. Unlike other conditions, such as cardiovascular disease and cancer, obesity has seen no widespread progress in management in recent years.
Recognition of obesity as a medical problem is a challenge in itself. Many people consider obesity to be a character fl aw or a behavioral issue and fail to recognize it as a disease entity. Yet obesity is the root cause of many metabolic conditions and diseases with metabolic components, including type 2 diabetes, heart disease, blood pressure, metabolic syndrome, acid refl ux, gout, arthritis, and sleep apnea.
The approach to obesity treatment can be conceptualized as a pyramid, with the aggressiveness of the intervention based on the patient's body mass index (BMI). At the base of the pyramid, for patients with lower BMIs, are minimally invasive (and minimally effective) interventions involving changes in diet, physical activity, and other lifestyle factors. As BMI increases, so does the intensity of treatment, to include pharmacotherapy and eventually bariatric surgery. Traditionally, surgery has been considered only at the very top of the pyramid, for morbidly obese patients, and is usually not offered as an option for the vast majority of people with this condition.
The sad reality is that the various combinations of these therapies are effective in fewer than 1% of the approximately 100 million Americans who are obese. Because surgery has been shown to be the most effective therapy for obesity, the remainder of my discussion will focus on surgery, with an eye toward potential new indications for bariatric procedures and the questions they raise.
SURGICAL APPROACHES TO OBESITY
Bariatric surgery has evolved over the past 50 years.
Although there are about a dozen different permutations of bariatric procedures performed in the United States today, they fall into one of three major types of operations, as outlined below:
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Gastric banding reduces appetite and satiety by adjusting and tightening the gastric band. This procedure has been in existence for 10 to 15 years and represents about 25% of operations for obesity in the United States.
The biliopancreatic diversion procedure diverts most of the small bowel and radically reduces absorption of calories. Patients undergoing this procedure lose weight because few calories are absorbed into the body. This approach, while quite effective, is somewhat radical and represents only about 2% of the operations for obesity in the United States.
The Roux-en-Y gastric bypass procedure has been the dominant procedure over the past 15 to 20 years. A combination of the above two procedures, it involves reducing the gastric reservoir and bypassing the stomach and upper intestine. The reduction in gastric volume reduces calorie intake by enhancing satiety, and the limited foregut bypass moderately reduces absorption.
No randomized trials, but much support from observational studies
Virtually none of these procedures evolved with randomized controlled trials. Instead, they evolved incrementally, primarily on the basis of knowledge gained from case procedures. Despite the lack of randomized trials, these operations have been shown to be effective, particularly in patients with multiple metabolic abnormalities associated with severe obesity. A large body of data from case-control and cohort studies demonstrates not only dramatic improvement in metabolic abnormalities with the use of various bariatric procedures, but also improvements in quality of life and survival. [20] [21] [22] [23] [24] [25] [26] The two most recent of these studies, published in 2007, found reductions in mortality of 29% (adjusted) and 40% among surgical patients compared with well-matched obese controls during mean followup of more than 7 years. 25, 26 Reductions in the incidence of cardiovascular mortality and, secondly, cancer-related mortality were the two major contributors to the overall mortality reduction in these two studies. Consistent with this latter fi nding, obesity is starting to be thought of as a disease that may lead to cancer. Payors adhere strictly to these indications, such that they will not pay for bariatric surgery in a patient with a BMI less than 35 kg/m 2 . This raises questions about the appropriateness of such a fi rm threshold and whether expansion of these strict indications may be reasonable.
NEW FRONTIERS FOR BARIATRIC PROCEDURES
Even without broadened indications, the volume of bariatric procedures in the United States has grown dramatically in recent years. Whereas only 10,000 to 20,000 of these operations were performed annually in the 1990s, approximately 200,000 such procedures were performed in 2007, and this number is expected to double over the next 5 years or so.
This growth in volume has been paralleled by burgeoning media interest in bariatric procedures, particularly in the last few years. More attention can be expected as we increasingly recognize the potential of bariatric procedures for indications beyond strictly the treatment of morbid obesity. At least two new frontiers loom: metabolic surgery and endoscopic surgery.
Metabolic surgery
Procedures that incorporate a bypassthe Roux-en-Y gastric bypass and the biliopancreatic diversion-have been associated with a reversal of metabolic diseases such as type 2 diabetes.
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Many patients with type 2 diabetes who have undergone these procedures have been able to be weaned off insulin and insulin-sensitizing medications while maintaining normal blood glucose levels. The effect has been profound and immediate, occurring even before the patient loses weight. In one series of patients with type 2 diabetes who had undergone a bypass operation, 30% left the hospital in a euglycemic state. 29 These observations have been made primarily in the morbidly obese population, who are the primary candidates for bariatric bypass procedures. However, because of the rapid improvement in metabolic abnormalities that has been observed, interest has arisen in applying these procedures to populations that are not morbidly obese. Bypassing of the foregut appears to be critical, perhaps because it tempers the release of hormonally active peptides from the gastrointestinal tract. 33 In any case, the gut is regaining recognition as a major metabolic organ.
In light of these hypotheses, the duodenal-jejunal bypass is a bariatric procedure that may be benefi cial for a patient with type 2 diabetes who is not morThe current indications for bariatric surgery have existed intact for about 25 years, and were based on limited evidence.
-Dr. Philip Schauer bidly obese. In this operation, the stomach volume is preserved but the foregut is bypassed. In a small experimental series from Brazil, patients with type 2 diabetes who were normal weight or only slightly overweight had resolution of their diabetes following this procedure, without any weight loss. 34 
New applications for endoscopy
Another area of development is endoluminal and transgastric bariatric surgery. Endoluminal surgery is performed entirely within the lumen of the gastrointestinal tract using fl exible endoscopy. Transgastric surgery is performed within the peritoneal cavity, which is accessed via a hollow viscus. Both approaches use natural orifi ces to gain surgical access, thereby avoiding access incisions and scars. 35 The benefi ts of such an approach are numerous: (1) fewer complications and side effects; (2) less invasiveness, and thus the ability to perform in the outpatient setting; (3) reduced procedure costs; and (4) better access to treatment. The implication in terms of indications is the potential to use such procedures to prevent progression to morbid obesity.
Examples of these procedures are proliferating: Gastrojejunostomy reduction is an endoscopic procedure that involves reducing the dilated opening of the gastric pouch after gastric bypass surgery. New endoscopic suturing or stapling devices enable the outlet reduction without requiring surgery. The result is enhancement of weight loss without a major operation.
Endoluminal suturing uses endoscopic instruments to suture the stomach to reduce its volume. When this procedure is perfected, the patient should be able to leave the endoscopy suite and return home within a few hours.
The duodenal sleeve is an avant garde concept in which an internal sleeve is threaded into the stomach and down the intestines. 36 The sleeve covers the absorptive surface of the small bowel, preventing absorption of nutrients to cause weight loss. This procedure has been shown to have a strong antidiabetic effect as well.
Clinical applications of these operations are emerging. An endoluminal sutured gastroplasty procedure to shrink stomach volume has been shown in a small clinical trial to cause loss of signifi cant excess body weight; the operation leaves no scars and is associated with a low risk of bleeding or any type of surgical complication. 37 A similar procedure is in development that involves staples instead of sutures.
How best to validate innovations moving forward?
As we move into these new eras of metabolic surgery and endoluminal and transgastric bariatric surgery, interesting questions arise. We as innovators and caregivers are ethically obligated to demonstrate reasonable safety and effi cacy before such new procedures are performed widely. Although some of these emerging procedures involve new devices that will go through the FDA review process, many are existing procedures for which indications may be expanded, while others are permutations of existing procedures for which no formal rules for validation exist. For new procedures that differ substantially from existing proven procedures but which do not require new devices, should we not be ethically bound to demonstrate safety and effi cacy even though they do not require FDA review? These are the challenges that await as innovation takes bariatric surgery to new frontiers.
Natural orifi ce transluminal endoscopic surgery: Too much too soon? By Christopher Thompson, MD, MHES
Although the endoscope has changed very little since the fi rst fi berscope was developed 50 years ago, the accessories and other instruments used in conjunction with the endoscope have changed remarkably. These include clips for hemostasis, ultrasonographic technology, and instruments for tissue dissection.
These advances in endoscopy, combined with advances in laparoscopic surgery, have led to the convergence of these two fi elds, culminating in the new fi eld of natural orifi ce transluminal endoscopic surgery (NOTES). In NOTES, the surgeon enters a natural orifi ce and punctures through a viscus to perform surgery, removes the endoscope, and closes the area without leaving a scar.
HISTORY OF NOTES AT A GLANCE
NOTES was patented as a concept in 1992. Its fi rst application was as an exploratory procedure in the pig in 2004. 38 Soon thereafter, therapeutic NOTES procedures in animals were reported, including tubal ligation, organ resection, cholecystectomy, and splenectomy.
Particularly notable in the development of NOTES is the extremely short interval between early animal experiments (2004) and the fi rst human procedures, which took place as early as 2005 when surgeons in India used the technique to perform a human appendectomy. Since then, more than 300 NOTES procedures have been performed in humans throughout the United States, Europe, Latin America, and Asia, for
INSIDE THE OPERATING ROOM
applications ranging from percutaneous endoscopic gastrostomy rescue to transvaginal cholecystectomy.
This rapid adoption of NOTES in humans is concerning, as it raises clear questions about whether there has been time for adequate oversight and safety assessment. For instance, at a surgical conference in April 2008, questions and debate swirled around whether a large Brazilian registry of more than 200 NOTES cases did or did not include two deaths. Other ethical issues raised by NOTES are discussed further below.
DRIVING FORCES BEHIND NOTES
The medical rationale Abdominal wounds can cause pain, are unaesthetic, and are prone to wound infections, ruptures, and hernias. They sometimes cause adhesions or may lead to abdominal wall syndromes with scar neuromas that cause pain later. They also require general anesthesia. Beyond these shortcomings of incision-based procedures, NOTES offers potential reductions in length of stay and therefore in cost. Moreover, certain patient populations may specifi cally stand to benefi t from NOTES, such as obese patients, those with abdominal mesh in place, and those undergoing palliative procedures. This is the essence of the medical rationale for NOTES, which is somewhat thin.
Professional organizations and courses
In July 2005, leaders from the American Society of Gastrointestinal Endoscopy and the Society of American Gastrointestinal and Endoscopic Surgeons convened a working group to support and plan for the responsible development of NOTES. 39 The group formed the Natural Orifi ce Surgery Consortium for Assessment and Research (NOSCAR), an organization that has since sponsored several conferences on NOTES and procured millions of dollars in grants for NOTES research in animals. (In the interest of full disclosure, I am one of the founding members of NOSCAR.)
Additionally, leading institutions in this fi eld have held numerous hands-on courses on NOTES throughout the United States, Europe, Latin America, and Asia. These courses, including those held by my laboratory at Harvard University, are designed to teach colleagues at other institutions how to set up an appropriate animal laboratory and to promote and encourage proper research in NOTES. There have been unintended consequences, however, as we have learned that some course attendees have returned to their home countries and immediately started using the techniques in humans.
New technology
At the July 2005 working group meeting that launched NOSCAR, we determined that several technological advances were needed before NOTES could be safely applied to humans. These included development of multitasking platforms, better devices for tissue apposition and fi xation, better imaging and spatial orientation, and improved means of retraction. 39 Industry responded with novel devices and end effectors such as guide tubes, direct drive systems, endoscopic suturing devices, magnetic retraction, devices for closing luminal defects, fl exible staplers, and computerized robotics.
Other driving forces
Additional forces have undoubtedly contributed to the rapid development of NOTES:
• The slowdown in innovation in general surgery in recent years has left a vacuum to be fi lled.
• An abundance of venture capital has been available to rush into that vacuum.
• Perceived patient demand (owing to cosmetic advantages) has been a driver, especially in cities such as Rio de Janeiro, Milan, and New York.
The fear of being left behind is a factor that can-• not be underestimated. Surgeons who failed to convert to laparoscopic techniques from open techniques in the early 1990s for procedures such as cholecystectomy, fundoplication, and splenectomy were losing their patient bases. Many surgeons fear a similar phenomenon today if they do not adopt NOTES into their practices.
ETHICAL ISSUES RAISED BY NOTES
As NOTES moves toward further evaluation in humans, several ethical questions need to be grappled with:
Must there be a signifi cant potential for improve-• ment in care before an innovation advances to human research?
Is the cosmetic benefi t of NOTES suffi cient, • considering the substantially increased risk? For instance, laparoscopic cholecystectomy is well estabThe fear of being left behind cannot be underestimated. Many surgeons fear they will lose their patient base if they do not adopt NOTES into their practices.
-Dr. Christopher Thompson lished, whereas NOTES cholecystectomy carries an increased risk of bile duct injuries and other injuries. Is NOTES worth the risk?
What about the corporate agenda behind new • technologies and its associated infl uence on the media?
Are hospital IRBs adequate to the task of evalu-• ating and monitoring these questions, and will they be independent of the impact of hospitals' larger agendas?
Finally, the problem of premature adoption of this technology is particularly concerning. I heard a surgeon explain at a course that he performed NOTES on a few pigs at a previous course and then returned home to Peru and immediately started performing it on patients at his ambulatory surgery center. There is also the temptation for well-respected surgeons to go to other countries to practice their NOTES skills before returning to the United States, in hopes that their experience will help them attain IRB approval. Practices like these raise questions about what ethical responsibilities lie with those of us who have pioneered the technology and are trying to develop and disseminate it responsibly. We can try to vigilantly watch course attendees from certain countries, but there is little we can do in the absence of regulation and enforcement in those countries. These are diffi cult ethical challenges. In bariatric surgery we are grappling with a procedure called the sleeve gastrectomy, which poses challenges comparable to lung volume reduction surgery as described by Dr. Cooper. Many of us believe that this procedure is just a slight modifi cation of a gastroplasty, yet payors consider it an entirely different procedure, and some want 5 to 10 years of follow-up data before they will pay for the operation.
Panel discussion
Dr. Joel Cooper:
That is not an easy question, but I would approach it from the standpoint of what you would tell the patient. When we were fi rst developing lung volume reduction, we performed it only in patients who had absolutely no other alternative. Only later in its development did we offer it as an alternative to transplantation. How do you approach the patient when you can already achieve a very good result with an existing procedure and you can tell the patient, with some assurance, what to expect with that procedure? In the case of NOTES, I do not think that the cosmetics are suffi cient justifi cation.
The second aspect is regulatory. I am not a supporter of the FDA's practices for the introduction of new procedures, but I believe strongly that universities have been derelict in setting the standard for the introduction of new procedures, particularly minimally invasive procedures. They have been using these procedures as marketing tools to vie with private hospitals for dollars and patients. I cannot say whether the rapid promulgation of these procedures at too early a stage actually can be prevented, but I do not recall the chairmen of major surgery departments getting together to issue public statements about the proper protocol for introducing new techniques. As Pogo said, "We have met the enemy and he is us."
This may not answer your question, but I believe there should be no payment for any new or novel procedure for a certain period after its introduction, and certainly the hospitals should not be able to profi t from it, although the expenses of a new procedure may be recouped. That alone would perhaps put the brake on some of the marketing and the fi nancial incentives, and it might separate, to some degree, the development of new procedures from economic interests.
WHO SHOULD OBTAIN INFORMED CONSENT?
Dr. Moreno: Should informed consent be obtained only by a knowledgeable third party rather than the surgeon-innovator?
Dr. Thomas Krummel: The question is whether there is a disinterested third party who truly is knowledgeable; in cases where there is such a person, I see no downside to having that person involved. However, the notion of having someone who is not associated with clinicians or surgeons obtaining informed consent makes me uncomfortable. Informed consent is not a piece of paper. It is a trust between physician and patient, and to ignore that could leave you in a heap of trouble.
Dr. Cooper: I agree, but another process is important as well. In proposing lung transplantation before
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there had been any successful transplants, we defi ned in advance the standards, indications, and contraindications that we thought should apply. We did this in the absence of any particular patient, and it relieved us of the diffi culty of making arbitrary decisions that may have led to unfairly accommodating one patient over another. Once the standards have been set in this way, they can be applied-whether by the investigator or by a committee-in an objective way to the group of patients that is most appropriate in the early phases of development.
Dr. Ralph Clayman:
It is diffi cult for the inventors of an operation to dampen their enthusiasm for their creation to a point where they are as objective as they should be. Joel is bringing up situations for which there are no alternatives. My realm is an area in which there were well-established alternatives for everything we have done laparoscopically or percutaneously, and it was diffi cult to decide the indications or contraindications early on. Often, the early indications only had to clear the threshold of not seeming ridiculous.
The early development of percutaneous stone removal at the University of Minnesota took place entirely outside the purview of an IRB. Percutaneous nephroscopy had been around since 1955, and we extended it to plucking out a stone. That is how that entire fi eld developed. Early on, we were not going to go after a stone that was as big as a fi st because we did not have a way to break it up. As time went by, however, it evolved to the point where there was no stone in the kidney-regardless of its size, location, or hardnessthat could not be removed through a small hole in the back. But that entire evolution proceeded without IRB approval.
For laparoscopic nephrectomy, for which there were well-known alternatives, who should have obtained the informed consent? Should it have been me, bringing along the "white coat" factor and not
Dr. Krummel: It is not unlike what we have tried at
Stanford when we are not sure of the boundary for IRB consultation. The surgical chairs are willing to convene and essentially police one another, so that when the neurosurgeon proposes a brain transplant, there probably will be a pretty interesting conversation before it gets the green light.
Dr. Cooper:
My experiences with IRB involvement differed quite a bit between my work in lung transplantation and my work in volume reduction surgery, but the differences owe a lot to the countries where I was practicing at the time. I did my early work in transplantation in Canada, where I did ask for approval from my hospital's ethics committee and other relevant committees. In Canada, the hospital had a global budget, and it made a decision that it was willing to use part of its budget for transplantation. We received no fees for years, until the operation was proven to be effective, but that did not stop us from developing the procedure. I had returned to the United States when I began my work with lung volume reduction, and I did not ask the IRB for permission to do that procedure. My justifi cation was that, theoretically, volume reduction was similar to accepted practices for removal of nonfunctioning lung to improve respiratory mechanics (bullectomy) and that we would simply be applying the concept to a different group of patients. However, unlike in Canada, I did not have institutional fi nancial support for doing this new procedure, so how was I going to do it if the hospital could not receive payment for it? I went to the IRB, but instead of asking for permission to do the procedure I asked for permission to study the procedure and to collect data on it. In that way, I was notifying the IRB of my action and thus giving it an opportunity to act. If I had gone to the IRB to approve the procedure, however, the operation would have been labeled experimental by insurance companies, who would have then found a way to deny payment. At least that was how it was in those days.
MARKETING OF MEDICINE: IS THERE NO TURNING BACK?
Question from audience: What makes you think that in 10 years there won't be 100 million obese Americans watching television ads for noninvasive bariatric surgery promising to rid them of their obesity problem? What will keep that from happening? 
Dr. Clayman:
We already have direct marketing of drugs and direct marketing of facilities. What Joel said is true: "the enemy is us." When I was in training, the idea that a physician would advertise was considered unethical. I still consider it thus. But everybody is doing it, so should that make it acceptable? I think not.
The same thing is true of the huge amount of money spent marketing drugs on television. Why should a single nickel be spent to advertise health care beyond generically informing the public of important health care issues and initiatives? You cannot go to an airport without seeing a surgical robotics program being advertised or a hospital being advertised. You cannot turn on National Public Radio without hearing wellfi nanced spots touting the achievements of a hospital. You cannot watch television without seeing ads for erectile dysfunction medications or other new drugs. It is a waste of dollars. If we took all of that money and redirected it, we could probably solve much of the indigent health care problem, but we as a society have chosen not to do that.
SHOULD THE BAR BE RAISED FOR SURGICAL TRIALS?
Dr. Moreno: Let's consider some additional questions. Why shouldn't the government raise the bar on the level of evidence needed to gain regulatory approval for new devices? Why not require randomized trials, as is done for drugs? Dr. Cooper: Procedures that lend themselves to a randomized trial should be studied at a limited number of centers with mandatory reporting and preset indications for promulgation and payment. I believe that universities have been derelict in their duty to require this level of evidence.
This question is always nuanced, however. Consider the case of laparoscopic procedures. They offer the advantage of smaller incisions, yet how many patients have had to die or suffer serious consequences for the sake of these smaller incisions? On the other hand, how many patients may have been saved from pulmonary embolism, wound infections, or a prolonged hospital stay as a result of laparoscopic techniques? Only a randomized trial could demonstrate whether or not there has been an overall payback from new procedures such as this, although even then the payback may be present for some types of patients but not others.
Dr. Schauer:
The problem is expense. Perhaps it is all a matter of economics. Return on investment for the drug industry is something like 10 to 1, but return on investment for the medical device industry is generally much lower. Therefore, conducting large randomized controlled trials is extremely expensive and much more complicated for a device or procedure. This may explain why the standard for trials is different for the two industries.
Dr. Krummel: Virtually all fetal surgical procedures have been subjected to a trial, several of them randomized. The National Institutes of Health paid for many of these trials. One such study prevented rapid uptake of the congenital diaphragmatic hernia operation, which has never been proven in a randomized trial to be better than our current therapy. It is a good example of a randomized trial making a difference.
Dr. Clayman:
As Joel pointed out, surgery is constantly evolving, whereas a drug remains unchanged throughout its lifespan. If we had started a prospective randomized trial after we had done our fi rst laparoscopic nephrectomy, the procedure would have died because we were not nearly as facile with our fi rst 10 as we were after our fi rst 100. The technology continues to develop, and the surgeon continues to develop his or her skills, which makes a study of this nature overly dynamic. Perhaps the best you can do is a retrospective, matched, controlled study with the same surgeon, comparing his or her results after 40 or 50 laparoscopic procedures with results after his or her 50 most recent open procedures.
Dr. Cooper:
How do you put a brake on the system? Would some sort of limited trial perhaps put a brake on the too-rapid promulgation that we often see? Dr. Clayman: In the general surgery realm, laparoscopic cholecystectomy came out of private practice. It did not come out of the university with its faculty and laboratories dedicated to exploration and investigation. It never was properly vetted in the scientifi c realm but rather came to the light of day as an "economic" edge. Dr. Schauer: I think the answer largely is fellowship training. Emerging procedures probably should be introduced in fellowship programs until they reach the point where they are so standardized that they become a major part of practice. For example, cholecystectomy quickly became part of general surgery practice, but laparoscopic colectomy took several years to evolve and was taught primarily in fellowship or advanced training, after which it gradually fi ltered down to residency programs.
Dr
Dr. Krummel: All of us who are responsible for training are wrestling with this problem. Residents are expected to learn more yet do so in less time. One approach would be early specialization, so that instead of 5 years of general surgery, you would have 3 years of general surgery and then 3 years of, for instance, thoracic surgery. Also, Ralph mentioned earlier the advantage of skills labs. We increasingly see that type of approach as a backbone for providing broad training without putting patients at harm.
As for teaching the use of new technology, fi rst you have to teach the existing base of practicing surgeons. Here again there is much to be said for skills labs, and I give credit to the American College of Surgeons for its drive to establish and accredit centers around the country as a way to teach this base of surgeons.
Dr. Schauer:
If I may expand this question beyond residency and fellowship training, how do we balance the desire to share new innovations with our colleagues against the need to temper their desire to prematurely jump into an area where they do not yet really belong? Chris, I know this applies to your challenges in disseminating knowledge about NOTES.
Dr. Christopher Thompson: Yes, courses on NOTES are also being held in conjunction with all the major society meetings, and we are seeing many enthusiastic trainees at these hands-on courses. The original intent was to give attendees instruction on setting up their own animal labs, yet some trainees took it beyond this limited purpose. As a result, some in our fi eld believe that we should not allow foreign physicians to come here to be trained in NOTES, for fear they will go back to their home countries and use it on humans. I am not certain that that approach is the best way to go, but there has been much discussion about how to handle this. It is a real conundrum. Certainly there are a number of surgical residents and gastroenterology fellows who are clamoring to get into the lab right now and learn these techniques.
Dr. Clayman:
This goes back to our earlier discussion about from where new technologies should emerge. What frightens me are the consequences of creative activity occurring outside the university, where there are no laboratories or animal or cadaver models for refi ning or testing a technique. To me, it was frightening to see laparoscopic cholecystectomy suddenly emerge as a craze without the proper animal and clinical studies having been done. That is not the way I believe clinical research should go forward. I once heard a prominent urologic surgeon say at a major surgical meeting, after a presentation on the impact of percutaneous stone surgery on the canine kidney, "Now that I've done a thousand of these in humans, it's reassuring to know that it's safe to do in dogs." That is not the way it should happen, and every time it does happen that way, we pay a large price, some of us as individuals and all of us as a society.
Dr. Cooper:
The answer therefore is to use our academic facilities to facilitate the training of those in community Some believe that we should not allow foreign physicians to come here to be trained in NOTES, for fear they will go back to their home countries and use it on humans.
-Dr. Christopher Thompson practice. We should continue to offer training because we have the resources to make it available.
Dr. Clayman: Yes, and this is why I emphasized earlier that support for surgical training centers is so essential. I see all the dollars spent on health care advertising and wonder why these dollars are not instead poured into surgical training, or research facilities, or training simulators.
The way we should train surgeons in new technologies is to train them on simulators equipped with a properly vetted curriculum. This is the future for training, because once you put instruments through small ports, everything becomes measurable-economy of motion, past pointing, and effi ciency; simulators with a curriculum will also be able to assess the trainee's cognitive abilities. When an individual performs well on the simulator, he or she can then come into the operating room and work with surgeons experienced in the procedure. The use of simulators in this manner should ultimately improve the overall quality and safety of each surgical specialty.
RISE OF THE ROBOTS
Question from audience: I am curious how the panel members interpret early randomized trial data showing an increased cost without an improvement in care with the use of surgical robots in certain procedures. Should we persist or consider an investment in the future as robotic technology improves and surgeons further adapt to it? Dr. Cooper: I think the robot should be used only for those procedures for which it has unique capability and can perform a task better than we can. It appears that the robot performs better than the ear, nose, and throat surgeon for operations on the base of the tongue. The same may be true of prostate surgery, but I am not certain. But to do a laparoscopic Nissen repair with a robot…as Dr. Nat Soper of Northwestern University has said, "If I needed a robot, I shouldn't be doing laparoscopic Nissens."
The robot provides light, it gives you magnifi cation, and it reduces tremor. We should concentrate on its use for operations where these attributes are particularly valuable. But we should be wary of its use as an expensive marketing tool.
Dr. Clayman:
The robot provides you with superhuman capabilities: 10 to 30ϫ magnifi cation, no tremor, a 540-degree wrist, instrumentation with 6 degrees of freedom, and motion scaling. It allows you to be a better surgeon than you are without it. I agree that it is expensive. It is woefully overpriced at this point, but I believe the expense will come down with time. It is no different than the fi rst computers, which were terribly expensive. The robot enables surgeons to do a better job than they would without it if we are talking about reconstructive-type surgery.
Ergonomically, the robot is very positive for the surgeon. For the fi rst time, the surgeon is actually allowed to sit down in a comfortable environment and can work for 4 hours straight, get up at the end of the surgery, and feel fi ne. If you are older than 50 and you operate standing at the table staring at a television screen on the other side for 4 to 6 hours, you are going to ache afterwards. I believe surgeons work better if they are comfortable.
Dr. Schauer:
At least within my fi eld of general surgery, there has been no evidence that this superhuman ability has translated into superhuman results, in terms of reduced operating time, fewer complications, or better effi cacy. We should probably develop the metrics to measure progress. How do the theoretical benefi ts translate into clinical benefi t?
Dr. Clayman: It is not theoretical in radical prostatectomy if you look at the data. The potency rates for patients who undergo robotic surgery for these procedures are now almost 90%, which is something that no surgeon performing open prostatectomy has ever achieved. Fortunately, the continence mechanism is so strong in most adults that it does not matter whether prostatectomy is done with a robot or open surgery-patients are probably going to be all right. But the bottom line is that robotic surgery is a bit better. Most surgeons would use it if it were free. The problem is that it is so expensive right now and it is breaking the backs of many hospitals.
You make a good point. Demonstrating metrics is important, and prostatectomy is a good example. But I am not aware of any other procedures for which benefi t from robotic surgery has been documented.
Dr. Krummel:
The history of robotic surgery is so interesting because the killer application was supposed to be coronary work-percutaneous bypass surgery. But then the heart port went to pot and patients with anterior wall lesions ended up not being a big The current robot is not an end device. We will see more. This theme of immediate benefi t versus follow-on iterations is the story of device development in this country.
-Dr. Thomas Krummel
